Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

PTPRD as a candidate druggable target for therapies for restless legs syndrome?

Full text
Author(s):
Morais, Milca A. [1] ; Franco, Beatriz [2] ; Holanda, Alessandro S. S. [1] ; Simino, Lais Angelica de Paula [1] ; Manconi, Mauro [3] ; Torsoni, Adriana [1] ; Esteves, Andrea M. [1]
Total Authors: 7
Affiliation:
[1] Univ Estadual Campinas, Fac Ciencias Aplicadas, St Pedro Zaccaria 1300, BR-13484350 Limeira - Brazil
[2] Univ Estadual Campinas, Fac Educ Fis, Campinas - Brazil
[3] Civ Hosp Lugano EOC, Neuroctr Southern Switzerland, Sleep & Epilepsy Ctr, Lugano - Switzerland
Total Affiliations: 3
Document type: Journal article
Source: Journal of Sleep Research; v. 30, n. 4 OCT 2020.
Web of Science Citations: 0
Abstract

The gene that encodes the protein tyrosine phosphatase D (PTPRD) may be related to brain circuits associated with sleep, and has been seen as an interesting molecule, a ``druggable{''} drug target. This gene is a potential candidate for increasing therapeutic advances in restless legs syndrome, a sleep-related movement disorder, that manifests as an uncontrollable desire to move limbs (legs) to relieve uncomfortable sensations. Changes in the PTPRD gene expression may increase the chance of developing this syndrome. Treatment with pramipexole is used in restless legs syndrome. This study aims to verify the effect of treatment with pramipexole on the PTPRD expression, as well as on the sleep pattern in an animal model for restless legs syndrome. For this, an animal model of sleep-related movement disorders (spontaneously hypertensive rats) was distributed in groups: (a) spontaneously hypertensive rats-control; (b) spontaneously hypertensive rats-pramipexole (0.125 mg kg(-1) for 4 weeks). The analyses of PTPRD gene and protein expression were performed in the striatum and spinal cord by quantitative real-time polymerase chain reaction and indirect enzyme-linked immunosorbent assay, respectively. Electrocorticographic and electromyographic analyses were performed. There was no difference in the PTPRD mRNA levels, as well as in the protein levels, although a tendency has been observed for decreased gene expression in the striatum and increased protein expression in the spinal cord in the spontaneously hypertensive rats-pramipexole group. Pramipexole improved the animals' sleep pattern. Thus, the treatment with pramipexole in the evaluated dose and time tended to alter the expression of the PTPRD protein in the spinal cord, in addition to significantly improving the sleep pattern. (AU)

FAPESP's process: 18/05245-5 - Effect of pharmacological and non-pharmacological treatment on the expression of the Protein Tyrosine Phosphatase, Receptor Type D(PTPRD) and its relation with the restless legs syndrome in SHR rats.
Grantee:Andrea Maculano Esteves
Support Opportunities: Regular Research Grants